Creative Biolabs spent decades of time and devotion exploring in the field of Proteolysis Targeting Chimeric (PROTAC), and is totally capable of providing associated molecular drug discovery solutions and highly qualified products (linkers, ligands, E3 ligase and target proteins, etc.), to prompt the development of new drug candidates from global customers.
Exploration never halts at Creative Biolabs, despite the fact that the rampaging COVID-19 is affecting the life and work of people across the whole New York City. Scientists at Creative Biolabs are working closely with the medicine manufacturers and researchers to improve and accelerate their drug discovery projects based upon the proteolysis targeting chimeric technology through offering professional technical support and comprehensive products, with the aim to seek for feasible alternative therapeutics and reduce the economic loss caused by the SARS-CoV-2.
PROTAC molecule discovery, PROTAC in vitro evaluation, and PROTAC in vivo animal test are the major solutions available, which are supported by scientists in the whole course and ensured for high-quality and on-time outcome delivery. The subdivisions are as follows, all of which can be provided separately or in package.
PROTAC molecule discovery covers the entire process of drug development, part of which is as follows.
• Ligand Design for Target Protein
• Ligand Screening for E3 Ubiquitin Ligase
• Linker Design and Optimization
• PROTAC Structural Modification
PROTAC in vitro evaluation modules are set up to testify the efficacy aspects of PROTACs, which include but are not limited to:
• Solubility and Chemical Stability
• Cell Permeability Efficacy
• Binary Target Engagement
Scientists will conduct PROTAC in vivo animal tests within the living mouse or rats to verify the safety.
• In Vivo Toxicity
• In Vivo ADME (absorption, distribution, metabolism, and excretion)
In addition to the solutions, there are also products such as ready-made PROTAC linkers of specific length, ligands of different functions (E3 ligase ligands, ligand-linker conjugates, target ligands, and intact PROTAC molecules), and E3 ligases and target proteins for in vitro high-throughput screening or other uses. Under current situation, the products are well stocked and ensured for on-time delivery.
PROTAC technology is currently an innovative approach getting a lot of attention. Creative Biolabs has confidence with its prospect since PROTAC based medicines get rid of the drawbacks of conventional small-molecule inhibitors, which can eliminate disease-causing proteins through degradation by the ubiquitin-proteasome system (UPS), eminently cutting down the toxicity, and prolonging the pharmacodynamics effect.
More relevant details can be reached at https://www.creative-biolabs.com/protac.
About Creative Biolabs
Creative Biolabs is an international company with almost 20 years of successful operation, headquartered in New York, USA. After years of extensive exploration and dedicated research, the scientific team is capable of offering professional and specialized solutions targeting PROTAC technologies, with a full list of PROTAC products available for global reach.